Abetimus Sodium Abetimus_Sodium http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Abetimus_Sodium D(C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A)DNA 5',5''',5''''',5'''''''-((1,2-Ethanediylbis(Oxy-2,1-Ethanediyloxycarbonylnitrilobis(2,1-Ethanediylimino(6-Oxo-6,1-Hexanediyl)Imino(2-Oxo-2,1-Ethanediyl)Thio-6,1-Hexanediyl))) Tetrakis(Hydrogen Phosphate)) Comp LJP-394 Deoxyribonucleic Acid D(C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A), 5'-Ester with 1,2-Ethanediylbis(Oxy-2,1-Ethanediyl)Bis(2-(21,21-Dihydroxy-4,11-Dioxo-20-Oxa-13-Thia-3,10-Diaza-21-Phosphaheneicos-1-Yl)-23,23-Dihydroxy-6,13-Dioxo-22-Oxa-15-Thia-2,5,12-Tria LJP 394 Riquent SubClass rdfs:subClassOf Immunomodulating Agent Biological_Response_Modifier http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Biological_Response_Modifier class rdfs:label Abetimus Sodium Concept_In_Subset FDA Established Names and Unique Ingredient Identifier Codes Terminology FDA_UNII_Code_Terminology http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#FDA_UNII_Code_Terminology class FDA_UNII_Code F5Y7739G6U FULL_SYN D(C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A)DNA 5',5''',5''''',5'''''''-((1,2-Ethanediylbis(Oxy-2,1-Ethanediyloxycarbonylnitrilobis(2,1-Ethanediylimino(6-Oxo-6,1-Hexanediyl)Imino(2-Oxo-2,1-Ethanediyl)Thio-6,1-Hexanediyl))) Tetrakis(Hydrogen Phosphate)) Comp Riquent LJP 394 LJP-394 Deoxyribonucleic Acid D(C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A), 5'-Ester with 1,2-Ethanediylbis(Oxy-2,1-Ethanediyl)Bis(2-(21,21-Dihydroxy-4,11-Dioxo-20-Oxa-13-Thia-3,10-Diaza-21-Phosphaheneicos-1-Yl)-23,23-Dihydroxy-6,13-Dioxo-22-Oxa-15-Thia-2,5,12-Tria code C87420 CAS_Registry 169147-32-4 SuperClass Immunomodulating Agent Biological_Response_Modifier http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Biological_Response_Modifier BRM Immunotherapeutic Agent Immunopotentiators Immunomodulators Immune Mediators Biomodulators Biological Response Modifier Immune Modulators Immune Regulators Immunomodulatory Agent Substances that enhance, restore or alter the host's immune system. Immunomodulating agents can be preventive or therapeutic and can suppress or activate the immune system, either directly or indirectly. For cancer treatment purposes, immunomodulating agents can be used to prevent or inhibit tumorigenesis. Examples of immunomodulators include, but are not limited to, cytokines, monoclonal antibodies and vaccines. SubClass rdfs:subClassOf Pharmacologic Substance Pharmacologic_Substance http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Pharmacologic_Substance class rdfs:label Immunomodulating Agent Legacy Concept Name Biological_Response_Modifier FULL_SYN Immune Modulators BRM Immune Regulators Immunopotentiators Biological Response Modifier Immunomodulators Immunomodulatory Agent Immune Mediators Biomodulators Immunotherapeutic Agent code C308 CHEBI_ID CHEBI:50846 DEFINITION Substances that enhance, restore or alter the host's immune system. Immunomodulating agents can be preventive or therapeutic and can suppress or activate the immune system, either directly or indirectly. For cancer treatment purposes, immunomodulating agents can be used to prevent or inhibit tumorigenesis. Examples of immunomodulators include, but are not limited to, cytokines, monoclonal antibodies and vaccines. InstanceCount 0 RdfType ChildCount 99 Semantic_Type Chemical Viewed Functionally UMLS_CUI C0005525 Preferred_Name Immunomodulating Agent class Chemical_Formula C1632H1944N610Na156O970P156S4 InstanceCount 0 RdfType ChildCount 0 Semantic_Type Pharmacologic Substance UMLS_CUI C0298633 Contributing_Source FDA Preferred_Name Abetimus Sodium class